{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T05:08:35Z","timestamp":1789708115638,"version":"4.0.1"},"reference-count":13,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100005918","name":"Christian Medical College Vellore","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005918","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Indian Journal of Medical Microbiology"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.ijmmb.2021.05.020","type":"journal-article","created":{"date-parts":[[2021,6,12]],"date-time":"2021-06-12T00:50:43Z","timestamp":1623459043000},"page":"534-536","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Clinical implications of high-risk mutations in drug resistant tuberculosis (DR-TB): An observational cohort study"],"prefix":"10.1016","volume":"39","author":[{"given":"Anupa","family":"Thampy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marilyn M.","family":"Ninan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joy S.","family":"Michael","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prince","family":"James","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priscilla","family":"Rupali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijmmb.2021.05.020_bib1","series-title":"India Tb report national tuberculosis","first-page":"292","author":"Central Tb Division - Directorate General of Health Services","year":"2020"},{"key":"10.1016\/j.ijmmb.2021.05.020_bib2","series-title":"Implementing the stop Tb strategy","author":"World Health Organization","year":"2008"},{"issue":"4","key":"10.1016\/j.ijmmb.2021.05.020_bib3","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1086\/590009","article-title":"Extensively drug-resistant tuberculosis in California, 1993\u20132006","volume":"47","author":"Banerjee","year":"2008","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.ijmmb.2021.05.020_bib4","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01299-16","article-title":"Molecular investigation of resistance to second line injectable drugs in multidrug-resistant clinical isolates of Mycobacterium tuberculosis in France","volume":"61","author":"Brossier","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"10.1016\/j.ijmmb.2021.05.020_bib5","doi-asserted-by":"crossref","first-page":"2961-2969","DOI":"10.1128\/JCM.01257-15","article-title":"Diagnostic performance of the new version (v2.0) of GenoType MTBDRsl assay for detection of resistance to fluoroquinolones and second-line injectable drugs: a multicenter study","volume":"53","author":"Tagliani","year":"2015","journal-title":"J\u00a0Clin Microbiol"},{"issue":"2","key":"10.1016\/j.ijmmb.2021.05.020_bib6","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.tube.2014.11.003","article-title":"Correlating Minimum Inhibitory Concentrations of ofloxacin and moxifloxacin with gyrA mutations using the genotype MTBDRsl assay","volume":"95","author":"Kambli","year":"2015","journal-title":"Tuberculosis"},{"issue":"3","key":"10.1016\/j.ijmmb.2021.05.020_bib7","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.ijmyco.2016.06.009","article-title":"Erratum: corrigendum to \u201cCorrelating rrs and eis promoter mutations in clinical isolates of Mycobacterium tuberculosis with phenotypic susceptibility levels to the second-line injectables","volume":"5","author":"Kambli","year":"2016","journal-title":"Int J Mycobacteriology Asian African Society for Mycobacteriology"},{"key":"10.1016\/j.ijmmb.2021.05.020_bib8","series-title":"Definitions and reporting framework for tuberculosis - 2013 revision (Issue 16)","author":"World Health Organization","year":"2020"},{"issue":"4","key":"10.1016\/j.ijmmb.2021.05.020_bib9","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1093\/jac\/dkr566","article-title":"A\u00a0systematic review of gyrase mutations associated with fluoroquinolone-resistant Mycobacterium tuberculosis and a proposed gyrase numbering system","volume":"67","author":"Maruri","year":"2012","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"2","key":"10.1016\/j.ijmmb.2021.05.020_bib10","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1093\/jac\/dkv360","article-title":"Specific gyrA gene mutations predict poor treatment outcome in MDR-TB","volume":"71","author":"Rigouts","year":"2016","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"3","key":"10.1016\/j.ijmmb.2021.05.020_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0229419","article-title":"Performance of Genotype MTBDRsl V2.0 over the Genotype MTBDRsl V1 for detection of second line drug resistance: an Indian perspective","volume":"15","author":"Rufai","year":"2020","journal-title":"PloS One"},{"issue":"1","key":"10.1016\/j.ijmmb.2021.05.020_bib12","first-page":"1","volume":"5","author":"Kambli","year":"2016","journal-title":"HHS Public Access"},{"issue":"2","key":"10.1016\/j.ijmmb.2021.05.020_bib13","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1089\/mdr.2011.0063","article-title":"Mutations in the rrs A1401G gene and phenotypic resistance to amikacin and capreomycin in Mycobacterium tuberculosis","volume":"18","author":"Sirgel","year":"2012","journal-title":"Microb Drug Resist"}],"container-title":["Indian Journal of Medical Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0255085721041220?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0255085721041220?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T19:19:07Z","timestamp":1759346347000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0255085721041220"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":13,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["S0255085721041220"],"URL":"https:\/\/doi.org\/10.1016\/j.ijmmb.2021.05.020","relation":{},"ISSN":["0255-0857"],"issn-type":[{"value":"0255-0857","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical implications of high-risk mutations in drug resistant tuberculosis (DR-TB): An observational cohort study","name":"articletitle","label":"Article Title"},{"value":"Indian Journal of Medical Microbiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijmmb.2021.05.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Indian Association of Medical Microbiologists. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}